

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 17th July 2025

FOI Ref No: 29582

Requested Information:

1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
 - Atezolizumab (Tecentriq)
 - Durvalumab (Imfinzi)
 - Nivolumab (Opdivo)
 - Pembrolizumab (Keytruda)
 - Chemotherapy
 - Radiotherapy
 - Chemotherapy AND Radiotherapy
 - Osimertinib

2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

3. How many patients has your Trust treated in total in the past 3 months for
 - Stage 2 Non-Small Cell Lung Cancer
 - Stage 3 Non-Small Cell Lung Cancer

4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
 - Atezolizumab
 - Pembrolizumab monotherapy
 - Pembrolizumab with chemotherapy
 - Nivolumab
 - Osimertinib
 - Durvalumab
 - Chemotherapy
 - Radiotherapy
 - Chemotherapy and Radiotherapy

5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:
 - Chemotherapy
 - Radiotherapy

- Chemotherapy + Radiotherapy
6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
- Durvalumab

Response:

Data from April to June 2025

1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
 - Atezolizumab (Tecentriq) **1**
 - Durvalumab (Imfinzi) **11**
 - Nivolumab (Opdivo) **1**
 - Pembrolizumab (Keytruda) **13**
 - Chemotherapy **3**
 - Radiotherapy **15**
 - Chemotherapy AND Radiotherapy **4**
 - Osimertinib **0**
2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? **6**
3. How many patients has your Trust treated in total in the past 3 months for
 - Stage 2 Non-Small Cell Lung Cancer **8**
 - Stage 3 Non-Small Cell Lung Cancer **23**
4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
 - Atezolizumab **1**
 - Pembrolizumab monotherapy **11**
 - Pembrolizumab with chemotherapy **1**
 - Nivolumab **1**
 - Osimertinib **0**
 - Durvalumab **11**
 - Chemotherapy **2**
 - Radiotherapy **5**
 - Chemotherapy and Radiotherapy **4**

5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:
- Chemotherapy **3**
 - Radiotherapy **1**
 - Chemotherapy + Radiotherapy **1**
6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
- Durvalumab **0**

Attachment(s):

No Attachment(s)

Date Response sent: 11th August 2025